WO2003016269A1 - 5-amidino-n-(2-aminophenethyl)-n-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor - Google Patents
5-amidino-n-(2-aminophenethyl)-n-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor Download PDFInfo
- Publication number
- WO2003016269A1 WO2003016269A1 PCT/JP2002/008093 JP0208093W WO03016269A1 WO 2003016269 A1 WO2003016269 A1 WO 2003016269A1 JP 0208093 W JP0208093 W JP 0208093W WO 03016269 A1 WO03016269 A1 WO 03016269A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lower alkyl
- hydrogen
- aminophenethyl
- amidino
- composition containing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108010074860 Factor Xa Proteins 0.000 abstract 2
- OSWRYKDLCXVVEV-UHFFFAOYSA-N 3-[2-(2-aminophenyl)ethylsulfamoyl]-4-hydroxybenzenecarboximidamide Chemical class NC(=N)C1=CC=C(O)C(S(=O)(=O)NCCC=2C(=CC=CC=2)N)=C1 OSWRYKDLCXVVEV-UHFFFAOYSA-N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002457482A CA2457482A1 (en) | 2001-08-09 | 2002-08-08 | 5-amidino-n-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor |
| EP02762759A EP1415983A4 (en) | 2001-08-09 | 2002-08-08 | 5-AMIDINO-N- (2-AMINOPHENETHYL) -N-HYDROXYBENZENSULFONAMIDE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING SAME, AND INTERMEDIATE USING SAME |
| JP2003521197A JPWO2003016269A1 (ja) | 2001-08-09 | 2002-08-08 | ５−アミジノ−ｎ−（２−アミノフェネチル）−２−ヒドロキシベンゼンスルホンアミド誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| US10/486,137 US7022689B2 (en) | 2001-08-09 | 2002-08-08 | 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor |
| US11/246,641 US20060111446A1 (en) | 2001-08-09 | 2005-10-11 | 5-Amidino-N-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, pharmaceutical use thereof, and intermediate therefor |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001242905 | 2001-08-09 | ||
| JP2001-242905 | 2001-08-09 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/246,641 Division US20060111446A1 (en) | 2001-08-09 | 2005-10-11 | 5-Amidino-N-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, pharmaceutical use thereof, and intermediate therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003016269A1 true WO2003016269A1 (en) | 2003-02-27 |
Family
ID=19073104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2002/008093 WO2003016269A1 (en) | 2001-08-09 | 2002-08-08 | 5-amidino-n-(2-aminophenethyl)-n-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7022689B2 (ja) |
| EP (1) | EP1415983A4 (ja) |
| JP (1) | JPWO2003016269A1 (ja) |
| CA (1) | CA2457482A1 (ja) |
| WO (1) | WO2003016269A1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006006490A1 (ja) * | 2004-07-08 | 2006-01-19 | Ono Pharmaceutical Co., Ltd. | スピロ化合物 |
| JP2025502833A (ja) * | 2021-12-29 | 2025-01-28 | ハンジョウ アダメルク ファームラボス インコーポレーテッド | 多置換ウラシル誘導体およびその調製方法ならびに適用 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4954085B2 (ja) | 2004-12-06 | 2012-06-13 | メディシノバ， インコーポレイテッド | 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト |
| US20080181876A1 (en) * | 2007-01-30 | 2008-07-31 | Johnson Kirk W | Methods for treating acute and subchronic pain |
| WO2008137012A1 (en) * | 2007-05-03 | 2008-11-13 | Avigen, Inc. | Use of a glial attenuator to prevent amplified pain responses caused by glial priming |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997030971A1 (en) * | 1996-02-22 | 1997-08-28 | The Du Pont Merck Pharmaceutical Company | M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS |
| WO2000059876A1 (fr) * | 1999-03-31 | 2000-10-12 | Kissei Pharmaceutical Co., Ltd. | Derives de 3-amidinobenzenesulfonamide, compositions medicales qui les contiennent, et produits intermediaires pour leur elaboration |
| WO2002028827A1 (fr) * | 2000-10-04 | 2002-04-11 | Kissei Pharmaceutical Co., Ltd. | Derives de 5-amidino-2-hydroxybenzenesulfonamide, compositions pharmaceutiques les contenant et leurs intermediaires de preparation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5942544A (en) * | 1996-02-22 | 1999-08-24 | Dupont Pharmaceuticals Company | α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors |
-
2002
- 2002-08-08 WO PCT/JP2002/008093 patent/WO2003016269A1/ja not_active Application Discontinuation
- 2002-08-08 CA CA002457482A patent/CA2457482A1/en not_active Abandoned
- 2002-08-08 US US10/486,137 patent/US7022689B2/en not_active Expired - Fee Related
- 2002-08-08 JP JP2003521197A patent/JPWO2003016269A1/ja active Pending
- 2002-08-08 EP EP02762759A patent/EP1415983A4/en not_active Withdrawn
-
2005
- 2005-10-11 US US11/246,641 patent/US20060111446A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997030971A1 (en) * | 1996-02-22 | 1997-08-28 | The Du Pont Merck Pharmaceutical Company | M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS |
| WO2000059876A1 (fr) * | 1999-03-31 | 2000-10-12 | Kissei Pharmaceutical Co., Ltd. | Derives de 3-amidinobenzenesulfonamide, compositions medicales qui les contiennent, et produits intermediaires pour leur elaboration |
| WO2002028827A1 (fr) * | 2000-10-04 | 2002-04-11 | Kissei Pharmaceutical Co., Ltd. | Derives de 5-amidino-2-hydroxybenzenesulfonamide, compositions pharmaceutiques les contenant et leurs intermediaires de preparation |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP1415983A4 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006006490A1 (ja) * | 2004-07-08 | 2006-01-19 | Ono Pharmaceutical Co., Ltd. | スピロ化合物 |
| JP2025502833A (ja) * | 2021-12-29 | 2025-01-28 | ハンジョウ アダメルク ファームラボス インコーポレーテッド | 多置換ウラシル誘導体およびその調製方法ならびに適用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2457482A1 (en) | 2003-02-27 |
| US20040242455A1 (en) | 2004-12-02 |
| US7022689B2 (en) | 2006-04-04 |
| EP1415983A4 (en) | 2006-01-18 |
| US20060111446A1 (en) | 2006-05-25 |
| JPWO2003016269A1 (ja) | 2004-12-02 |
| EP1415983A1 (en) | 2004-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1400529A4 (en) | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF | |
| EP1548008A4 (en) | COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING | |
| WO2005097129A3 (en) | 6-azaindole compound | |
| WO2006113552A3 (en) | Cyanoarylamines | |
| EP1396493A4 (en) | HETEROCYCLIC COMPOUNDS | |
| WO2003011880A1 (fr) | Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition | |
| AU1025795A (en) | Prolineamide derivatives | |
| GB0206860D0 (en) | Compounds | |
| WO2002044192A1 (fr) | Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions | |
| CA2336909A1 (en) | Thiobenzimidazole derivatives which are useful as inhibitors of human chymase activity | |
| EP1020434A4 (en) | 3-AMIDINOANILINE DERIVATIVES, INHIBITORS OF THE ACTIVATED BLOOD COINTENANCE FACTOR X AND INTERMEDIATE PRODUCTS FOR PRODUCING BOTH | |
| WO2003024955A3 (en) | Small molecule inhibitors of caspases | |
| WO2002010154A3 (en) | Substituted heterocyclic amides | |
| CA2398620A1 (en) | Pyrazine derivatives, pharmaceutical compositions containing them, and intermediates therefor | |
| WO2004014868A3 (en) | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | |
| WO2004014869A3 (en) | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors | |
| WO2004031145A3 (en) | Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors | |
| WO2000068198A3 (en) | Heterosubstituted pyridine derivatives as pde 4 inhibitors | |
| WO2004037796A3 (en) | 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | |
| MXPA05012274A (es) | Derivado de cianofluoropirrolidina. | |
| WO2003074513A3 (en) | Indole amide derivatives and their use as glycogen phosphorylase inhibitors | |
| NO20052182L (no) | Nye forbindelser | |
| EP1491187A4 (en) | PREVENTIVE OR THERAPEUTIC AGENT FOR RENAL DISEASES | |
| WO2002098850A3 (en) | Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors | |
| WO2002028827A1 (fr) | Derives de 5-amidino-2-hydroxybenzenesulfonamide, compositions pharmaceutiques les contenant et leurs intermediaires de preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2003521197 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10486137 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2457482 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002762759 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2002762759 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2002762759 Country of ref document: EP |